Roche said it plans to begin a Phase 2 trial combining petrelintide and enicepatide this year, betting that dual-incretin or multi-mechanism targeting could deliver a safety and efficacy advantage. The move escalates Roche’s competition in obesity and diabetes as other GLP-1 and next-generation obesity programs continue to expand across dosing regimens and patient populations.